Metabolomic Analysis of Vitamin E Supplement Use in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Jung-Eun LimHyokyoung G HongStephanie J WeinsteinMary C PlaydonAmanda J CrossRachael Stolzenberg-SolomonNeal D FreedmanJiaqi HuangDemetrius AlbanesPublished in: Nutrients (2023)
The effects of vitamin E supplementation on cancer and other chronic diseases are not clear. We compared the serum metabolomic profile of differing vitamin E dosages in order to re-examine the previously observed changes in a novel C 22 lactone sulfate compound, androgenic steroids, and other metabolites. A total of 3409 women and men previously selected for metabolomics studies in the PLCO Cancer Screening Trial were included in this investigation. Serum metabolites were profiled using ultrahigh-performance liquid and gas chromatography/tandem mass spectrometry. Seventy known metabolites including C 22 lactone sulfate and androgens were significantly associated with vitamin E supplementation. In the sex-stratified analysis, 10 cofactors and vitamins (e.g., alpha-CEHC sulfate and alpha-CEHC glucuronide), two carbohydrates (glyceric and oxalic acids), and one lipid (glycocholenate sulfate) were significantly associated with vitamin E dose in both males and females (FDR-adjusted p -value < 0.01). However, the inverse association between C 22 lactone sulfate and daily vitamin E supplementation was evident in females only, as were two androgenic steroids, 5-androstenediol and androsterone glucuronide. Our study provides evidence of distinct steroid hormone pathway responses based on vitamin E dosages. Further studies are needed to gain biological insights into vitamin E biochemical effects relevant to cancer and other chronic diseases.
Keyphrases
- tandem mass spectrometry
- gas chromatography
- papillary thyroid
- ultra high performance liquid chromatography
- mass spectrometry
- squamous cell
- liquid chromatography
- high performance liquid chromatography
- clinical trial
- study protocol
- prostate cancer
- simultaneous determination
- high resolution mass spectrometry
- phase iii
- type diabetes
- lymph node metastasis
- high resolution
- metabolic syndrome
- physical activity
- insulin resistance
- adipose tissue
- fatty acid
- open label
- gas chromatography mass spectrometry
- benign prostatic hyperplasia
- double blind
- placebo controlled